Page 3 - ஓவர்‌ஸீஸ் வணிக News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article TAIPEI, TAIWAN and EMERYVILLE, Calif., Jan. 25, 2021 /PRNewswire/ Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO) a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that the first participant has been dosed in the Phase 2 clinical trial evaluating MVC s COVID-19 vaccine candidate, MVC-COV1901.  MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax. MVC s Phase 2 clinical trial is a randomized, double-blinded, multi-center clinical trial, expecting to enroll 3,700 healthy subjects, 20 years of age and above. The trial will evaluate MVC-COV1901 safety and endurance of immunogenicity. The proposed dosing regimen is two doses administered intramuscularly one month apart. Based on MVC

T ai peiDerek coleRyan spencerNicole arndtPaul torkehagenCharles chenMedigen vaccine biologics corporationPrnewswire medigen vaccine biologics corporation mvc tpexDrug administrationDynavax technologies corporation nasdaqExchange commissionInvestor relations advisory solutionsMedigen vaccine biologics corpBusiness developmentVaccine biologics corporationDynavax technologies corporation